MediWound’s (MDWD) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of MediWound (NASDAQ:MDWD) in a research note issued to investors on Friday,Benzinga reports. HC Wainwright currently has a $25.00 price objective on the biopharmaceutical company’s stock.

MediWound Stock Performance

MDWD stock opened at $16.72 on Friday. The company has a market capitalization of $180.34 million, a P/E ratio of -5.77 and a beta of 0.80. The company has a fifty day moving average price of $17.24 and a 200-day moving average price of $17.66. MediWound has a 52-week low of $11.04 and a 52-week high of $24.00.

MediWound (NASDAQ:MDWD) last announced its earnings results on Tuesday, November 26th. The biopharmaceutical company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.50). MediWound had a negative return on equity of 82.17% and a negative net margin of 142.29%. During the same period last year, the company earned ($0.24) EPS. As a group, sell-side analysts forecast that MediWound will post -2.6 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. MetLife Investment Management LLC acquired a new position in MediWound in the third quarter valued at $89,000. Rhumbline Advisers bought a new position in shares of MediWound in the 2nd quarter worth about $131,000. Barclays PLC lifted its stake in shares of MediWound by 311.3% in the 3rd quarter. Barclays PLC now owns 11,163 shares of the biopharmaceutical company’s stock valued at $202,000 after purchasing an additional 8,449 shares during the period. Point72 Asset Management L.P. bought a new stake in shares of MediWound during the 3rd quarter valued at about $212,000. Finally, Bank of New York Mellon Corp acquired a new stake in MediWound during the second quarter worth approximately $342,000. Institutional investors and hedge funds own 46.83% of the company’s stock.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.